Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Radioligand therapy for mCRPC

Thomas Hope, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the use of radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Dr Hope specifically highlights the VISION trial (NCT03511664), which is investigating the use of 177Lu-PSMA-617 in this patient population. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.